Log in

Relevant bibliographies by topics / Stage II patients / Dissertations / Theses

Dissertations / Theses on the topic 'Stage II patients'

To see the other types of publications on this topic, follow the link: Stage II patients.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 16 dissertations / theses for your research on the topic 'Stage II patients.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Tsikitis, Vassiliki, David Larson, Marianne Huebner, Christine Lohse, and Patricia Thompson. "Predictors of recurrence free survival for patients with stage II and III colon cancer." BioMed Central, 2014. http://hdl.handle.net/10150/610351.

Full text

Abstract:

BACKGROUND:The aim of this study was to evaluate clinico-pathologic specific predictors of recurrence for stage II/III disease. Improving recurrence prediction for resected stage II/III colon cancer patients could alter surveillance strategies, providing opportunities for more informed use of chemotherapy for high risk individuals.METHODS:871 stage II and 265 stage III patients with colon cancers were included. Features studied included surgery date, age, gender, chemotherapy, tumor location, number of positive lymph nodes, tumor differentiation, and lymphovascular and perineural invasion. Time to recurrence was evaluated, using Cox's proportional hazards models. The predictive ability of the multivariable models was evaluated using the concordance (c) index.RESULTS:For stage II cancer patients, estimated recurrence-free survival rates at one, three, five, and seven years following surgery were 98%, 92%, 90%, and 89%. Only T stage was significantly associated with recurrence. Estimated recurrence-free survival rates for stage III patients at one, three, five, and seven years following surgery were 94%, 78%, 70%, and 66%. Higher recurrence rates were seen in patients who didn't receive chemotherapy (p=0.023), with a higher number of positive nodes (p<0.001). The c-index for the stage II model was 0.55 and 0.68 for stage III.CONCLUSIONS:Current clinic-pathologic information is inadequate for prediction of colon cancer recurrence after resection for stage II and IIII patients. Identification and clinical use of molecular markers to identify the earlier stage II and III colon cancer patients at elevated risk of recurrence are needed to improve prognostication of early stage colon cancers.

APA, Harvard, Vancouver, ISO, and other styles

2

Dobriansky, V. V. "Risk factors for recurrent hypoglycemia in patients with type II diabetes mellitus in the prehospital stage." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Obayashi(Nishiuchi), Aya. "MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer." Kyoto University, 2020. http://hdl.handle.net/2433/253179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Brand, Juanita M. "The lived experiences of six women during adjuvant chemotherapy for Stage I or II breast cancer." Virtual Press, 2005. http://liblink.bsu.edu/uhtbin/catkey/1317926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Caie, Peter David. "Discovery of novel prognostic tools to stratify high risk stage II colorectal cancer patients utilising digital pathology." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/19527.

Full text

Abstract:

Colorectal cancer (CRC) patients are stratified by the Tumour, Node and Metastasis (TNM) staging system for clinical decision making. Additional genomic markers have a limited utility in some cases where precise targeted therapy may be available. Thus, classical clinical pathological staging remains the mainstay of the assessment of this disease. Surgical resection is generally considered curative for Stage II patients, however 20-30% of these patients experience disease recurrence and disease specific death. It is imperative to identify these high risk patients in order to assess if further treatment or detailed follow up could be beneficial to their overall survival. The aim of the thesis was to categorise Stage II CRC patients into high and low risk of disease specific death through novel image based analysis algorithms. Firstly, an image analysis algorithm was developed to quantify and assess the prognostic value of three histopathological features through immuno-fluorescence: lymphatic vessel density (LVD), lymphatic vessel invasion (LVI) and tumour budding (TB). Image analysis provides the ability to standardise their quantification and negates observer variability. All three histopathological features were found to be predictors of CRC specific death within the training set (n=50); TB (HR =5.7; 95% CI, 2.38-13.8), LVD (HR =5.1; 95% CI, 2.04-12.99) and LVI (HR =9.9; 95% CI, 3.57- 27.98). Only TB (HR=2.49; 95% CI, 1.03-5.99) and LVI (HR =2.46; 95%CI, 1 - 6.05), however, were significant predictors of disease specific death in the validation set (n=134). Image analysis was further employed to characterise TB and quantify intra-tumoural heterogeneity. Tumour subpopulations within CRC tissue sections were segmented for the quantification of differential biomarker expression associated with epithelial mesenchymal transition and aggressive disease. Secondly, a novel histopathological feature ‘Sum Area Large Tumour Bud’ (ALTB) was identified through immunofluorescence coupled to a novel tissue phenomics approach. The tissue phenomics approach created a complex phenotypic fingerprint consisting of multiple parameters extracted from the unbiased segmentation of all objects within a digitised image. Data mining was employed to identify the significant parameters within the phenotypic fingerprint. ALTB was found to be a more significant predictor of disease specific death than LVI or TB in both the training set (HR = 20.2; 95% CI, 4.6 – 87.9) and the validation set (HR = 4; 95% CI, 1.5 – 11.1). Finally, ALTB was combined with two parameters, ‘differentiation’ and ‘pT stage’, which were exported from the original patient pathology report to form an integrative pathology score. The integrative pathology score was highly significant at predicting disease specific death within the validation set (HR = 7.5; 95% CI, 3 – 18.5). In conclusion, image analysis allows the standardised quantification of set histopathological features and the heterogeneous expression of biomarkers. A novel image based histopathological feature combined with classical pathology allows the highly significant stratification of Stage II CRC patients into high and low risk of disease specific death.

APA, Harvard, Vancouver, ISO, and other styles

6

Hendrix, Ryan J. "Improved Survival after Administration of Neoadjuvant Chemotherapy in Patients with Clinical Stage I/II Pancreatic Ductal Adenocarcinoma." eScholarship@UMMS, 2019. https://escholarship.umassmed.edu/gsbs_diss/1029.

Full text

Abstract:

Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of US cancer related deaths. This study assessed the oncologic benefit of a neoadjuvant chemotherapy (NAC) treatment strategy for patients with clinical Stage I/II PDAC. Methods: Patients with biopsy confirmed PDAC and clinical Stage I/II disease were treated with a protocol of NAC. The primary study endpoint was median overall survival (OS). Kaplan-Meier survival curves were compared using the log-rank test. Results: 56 patients met inclusion criteria. Of these, 21 patients (38%) had Stage I disease and 35 (62%) had Stage II disease. The median OS for the entire study population was 18.7 months. A total of 22 (39%) patients were managed with NAC+S; 34 (61%) received NAC alone. Median OS and 2-year survival rates were greater in those completing NAC+S compared to NAC alone (median OS 28.8 months vs. 17.3 months: p=0.05; 2-year OS: 55% vs 21%: p=0.01) . Interestingly, patients managed with NAC who were not candidates for surgical resection after restaging demonstrated a survival advantage (17.3 months) compared to what was previously reported in historical controls. Conclusion: NAC+S provided a significant 11.5 month improvement in median OS compared to treatment with NAC alone. Modern NAC may contribute a significant oncologic benefit in the overall treatment strategy for patients with Stage I/II PDAC, even if surgery is not ultimately pursued.

APA, Harvard, Vancouver, ISO, and other styles

7

Morris, Melinda. "Clinical and pathological predictors of survival for stage II and III colon cancer patients treated with or without chemotherapy : a population-based study." University of Western Australia. School of Surgery and Pathology, 2007. http://theses.library.uwa.edu.au/adt-WU2008.0012.

Full text

Abstract:

[Truncated abstract] Clinical and pathological predictors of survival for stage II and III colon cancer patients treated with or without chemotherapy: a population-based study. Aim: Using a population-based cohort of colorectal cancer (CRC), the major aims of this study were to: 1. Identify clinico-pathological markers that can be used to define a subset of stage II colon cancer patients with excellent prognosis and who therefore do not require referral for adjuvant chemotherapy; 2. Investigate whether there is a survival benefit from the use of adjuvant chemotherapy in a population-based cohort of stage II colon cancer; 3. Investigate stage III colon cancer patients for evidence of predictive markers for response to 5FU chemotherapy; 4. Investigate CRC for age-related differences in clinico-pathological and molecular features. Hypotheses to be tested: 1. A subset of good prognosis stage II colon cancers can be defined using routine pathological markers; 2. Females colon cancer patients gain more survival advantage from 5FU chemotherapy than males; 3. Tumours from young CRC patients have different molecular characteristics to those from older patients; 4. The underlying molecular characteristics of tumour can impact upon the response to 5FU chemotherapy. Methods: The study cohort consisted of 5,971 cases diagnosed between 1993 and 2003 representing over 90% of the CRCs diagnosed in the state of Western Australia. Results: The major findings of this translational research into colon cancer can be summarized as follows: The morphological features of serosal and vascular invasion allow for prognostic stratification of stage II colon cancer into

APA, Harvard, Vancouver, ISO, and other styles

8

Schrama, Jolanda Godefrida. "Patient selection for high-dose chemotherapy in stage II and IV breast cancer." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2004. http://dare.uva.nl/document/75451.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

MAIGNE, PHILIPPE. "Traitement de la maladie de hodgkin stade i-ii par radiotherapie exclusive : a propos de 67 patients du centre claudius regaud." Toulouse 3, 1993. http://www.theses.fr/1993TOU31057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

POURRAT, CHABROLET CORINNE. "Arteriopathie obliterante des membres inferieurs et hypertension arterielle : suivi longitudinal sur 10 ans d'une population de 125 patients du stade ii ; royat 1984-1993." Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1M026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hamy, Anne-Sophie. "Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer Neoadjuvant treatment : the future of patients with breast cancer Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an “option” but an ethical obligation Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status BIRC5 (survivin) : a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS129.

Full text

Abstract:

La chimiothérapie néoadjuvante (CNA) est utilisée dans les cancers du sein agressifs ou localement avancés (CS). Au delà des bénéfices cliniques, elle représente une opportunité pour monitorer in vivo la sensibilité d’une tumeur à un traitement.A partir de l’analyse de sets de données de patients traités par CNA, nous souhaitons identifier des mécanismes associes à la résistance ou sensibilité au traitement. Dans la première partie, nous avons évalué des paramètres, cliniques, anatomopathologiques et transcriptomiques. Nous avons démontré que des éléments non explorés comme la présence d’embols après CNA revêtaient une information pronostique importante. Dans une 2ème partie, nous avons analysé l’impact de l’infiltrat immunitaire dans le cancer du sein, et avons décrit les changements observés entre des échantillons avant et après CNA. Nous avons montré que l’impact pronostique des TILs était différent avant et après CNA, et était opposé dans les CS triple négatif ou HER2-positif. Finalement, nous avons analysé l’impact des comédications pendant la CNA. Nous avons trouvé des effets positifs – via l’augmentation de l’infiltrat immunitaire et la réponse au traitement – et des effets négatifs avec des effets délétères dans certains sous groupes de patients. En conclusion, la situation néoadjuvante représente une plateforme pour générer et potentiellement valider des hypothèses de recherche. La mise à disposition de jeux de données de patients traités par chimiothérapie néoadjuvante constituerait une ressource majeure pour accélérer la recherche contre le cancer du sein
Neoadjuvant chemotherapy (NAC i.e. chemotherapy before surgery) is increasingly being used for aggressive or locally advanced breast cancer (BCs). Beyond clinical benefits, it represents an opportunity to monitor in vivo sensitivity to treatment. Based on the analysis of datasets of BCs patients treated with NAC, we aimed at identifying mechanisms associated with resistance or sensitivity to treatment.In the first part, we evaluated biological, clinical, pathological and transcriptomic patterns. We demonstrated that unexplored pathological features such as post-NAC lymphovascular invasion may carried an important prognostic information.In a second part, we analyzed impact of imune infiltration in BC and we described extensively the changes of tumor infiltrating lymphocytes (TILs) between pre and post-NAC samples. We showed that the prognostic impact of TILs was different before and after NAC, and was opposite in TNBC and HER2-positive BCs. Finally, we investigated the impact of comedications use during NAC. We found both positive effects - while enhancing immune infiltration and response to treatment - and negative effects with deleterisous oncologic outcomes in specific patients subgroups. In conclusion, the neoadjuvant setting represents a platform to both generate and potentially validate research hypotheses aiming at increasing the efficacy of treatment. The public release of real-life datasets of BC patients treated with NAC would represent a major resource to accelerate BC research

APA, Harvard, Vancouver, ISO, and other styles

12

松本, 高明, and T. Matsumoto. "Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly." Thesis, 2013. http://hdl.handle.net/2237/18452.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lima, Isac da S. F. "Effects of Timing of Adjuvant Treatment on Survival of Patients with Stage III Colon Cancer and Stage II/III Rectal Cancer in Alberta." Master's thesis, 2010. http://hdl.handle.net/10048/1341.

Full text

Abstract:

Surgery followed by adjuvant treatment has been an evidence-based treatment recommendation for stage III colon cancer and stage II/III rectal cancer since 1990. Clinical trial results are, however, uninformative regarding the definitive outer limit by which adjuvant treatment should be received for optimal survival benefit. The purpose of my thesis research was to assess the effect that the timing of adjuvant therapy has on patient survival in actual clinical practice
Epidemiology

APA, Harvard, Vancouver, ISO, and other styles

14

Huang, Ming Ming. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." 2004. http://www.cetd.com.tw/ec/thesisdetail.aspx?etdun=U0007-1704200714553714.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Ming, Huang Ming, and 黃明明. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." Thesis, 2004. http://ndltd.ncl.edu.tw/handle/06969937429915668897.

Full text

Abstract:

碩士
臺北醫學大學
保健營養學系
92
Abstract In Taiwan, the incidence rate of female breast cancer has been increasing gradually every year, and has been the 4th leading cause of cancer death. This study was aimed to explore the effect of postoperative adjuvant chemotherapy (C/T) and radiotherapy (R/T) on serum copper, zinc, Cu/Zn ratio and RBC-SOD in female breast cancer patients. In the meantime, we analyzed the dietary intake and body weight change to understand whether the serum trace elements status of the patients were influenced by diet, C/T, or R/T. Results obtained from this study may provide some information for adequate nutrition support in clinical practice in the future. The results showed that serum copper, zinc, Cu/Zn ratio and RBC-SOD were not significantly different before and after C/T and R/T treatment in patients. During postoperative treatment, Cu/Zn ratio did not show significant difference, but a significantly positive correlation trend between several measurement was noted. Dietary zinc and protein intake did not significantly correlated with serum copper and zinc status. Calorie intake increased 300-100 Kcal/d and body weight showed an elevated trend with 3% increase after the postoperative treatment started, however, there were no obvious changes than before. The percentage of macronutrients intake were in normal ranges. Protein intake increased from 1.17 g/ kg BW to 1.39 g/kg BW when postoperative treatment began, and zinc intake was higher during treatment period, but showed no significant difference. The level of zinc intake was below RDNA before and after treatment. In conclusion, postoperative adjuvant chemotherapy and radiotherapy did not affect serum copper , zinc, Cu/Zn ratio and RBC-SOD in stage II breast cancer patients who take balance diet containing adequate amount of copper and zinc. Keywords: breast cancer, chemotherapy, radiotherapy, Cu, Zn, SOD

APA, Harvard, Vancouver, ISO, and other styles

16

Chiang, Fu-Fan, and 蔣馥帆. "The Application of Data Mining Techniques to the Prognosis of Stage II Colorectal Cancer Patient." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/5783bz.

Full text

Abstract:

碩士
國立中正大學
資訊管理學系暨研究所
102
According to the annual cancer registration report by the Health Promotion Administrative, Ministry of Health and Welfare in 2010, the deaths of Colorectal Cancer Malignancies was 11.39% of all malignancies. The ranking of the death rate was the third, and the number of cases was the first among the malignancies in Taiwan. 　　Based on the statistics by a medical center in Taiwan, the cancer registration data base from 2007 to 2009, the patients in the stage II of Colorectal Cancer ranked the highest percentage ; the stage III was the second, and the stage IV was the third. 　　This study collected the data of 283 patients from January 2003 to December 2009 in a medical center in Taiwan and applies the Decision Tree (DT), the Logistic Regression, and the Artificial Neural Networks (ANNs) to construct the survival prediction model of the Colorectal Cancer. 　　The current study found that the constructed model of the Data Mining was the most appropriate by utilizing the ANNs. The accuracy was 74.56% (the ROC curve was 83%). The accuracy of the Decision Tree ranked second which was 73.14% (the ROC curve was 72%). The last one was the Logistic Regression and the accuracy was 71.73% (the ROC curve was 75%). 　　According to these three models, eventually the survival of the patients in the stage II of the Colorectal Cancer can be predicted. These three models provide the survival prediction for the patients in the stage II of the Colorectal Cancer and provide suggestions and references for doctors to conduct treatment and evaluation.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!